Insights On CONTRACT PHARMA MANUFACTURING

31. Increasing Batch Size And Reducing Cycle Times For A Biologic 8/5/2025

    JHS partnered with a global pharma company to optimize biologic production, increasing output by 50% and reducing batch release times by up to 30%.

32. AI Predictive Maintenance Prevents Batch Loss And Production Shutdown 8/5/2025

    AI-powered predictive maintenance with wireless vibration sensors prevented costly batch loss and production shutdowns in pharma manufacturing by detecting and fixing equipment issues before failures occurred.

33. Random & Semi-Targeted Integration In Cell Line Development 8/5/2025

    Compare random and semi-targeted integration strategies for stable cell line development, highlighting their impact on expression consistency, scalability, and regulatory considerations.

34. Site-Specific Conjugation For Next-Gen ADCs 8/4/2025

    Unlock the full potential of your ADCs with a site-specific conjugation platform that delivers unmatched stability, homogeneity, and therapeutic performance.

35. Optimizing Cell Therapy Analytics Through DoE Methodologies 8/4/2025

    Design of Experiment (DoE) methods streamline the development of robust, phase-appropriate potency and functional assays, ensuring consistent, efficient, and regulatory-aligned testing that supports scalable cell therapy development.

36. Continuous Manufacturing For API Breakthroughs 7/31/2025

    Observe how a compound library, designed for chemical diversity and lead-like properties, uses advanced filtering to improve hit discovery, speed hit-to-lead development, and boost early-stage small molecule drug discovery.

37. Integrating Cutting-Edge Technologies In Cell Bank Manufacturing 7/31/2025

    Discover how our adoption of a counterflow centrifuge enhances GMP-compliant cell banking through closed-system automation, precision harvesting, and scalable workflows.

38. Accelerated Tech Transfer With Integrated, Client-Focused Project Management 7/30/2025

    Observe how integrated project management and co-located DS/DP operations streamline technology transfer, reduce risks, and accelerate biopharmaceutical development timelines.

39. Lentiviral Vectors: The Key To Cell And Gene Therapy Success 7/30/2025

    Lentiviral vector manufacturing is complex and highly regulated, which is why a specialized CDMO is required to ensure safe, scalable, and compliant production from early development to commercialization.

40. Leverage Process Analytical Technology For Developing Novel Conjugates 7/29/2025

    Explore how Process Analytical Technology accelerates novel conjugate development and how PAT is integrated with an ADC platform to enhance efficiency, data quality, and product consistency.